Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia

Laurence C. Cheung; Mark N. Cruickshank; Anastasia M. Hughes; Sajla Singh; Grace-Alyssa Chua; Jette Ford; Emanuela Ferrari; Joyce Oommen; Sebastien Malinge; Richard B. Lock; Ursula R. Kees; Rishi S. Kotecha

doi:10.3324/haematol.2018.192906

Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia

Laurence C. Cheung
, Mark N. Cruickshank
, Anastasia M. Hughes
, Sajla Singh
, Grace-Alyssa Chua
, Jette Ford
, Emanuela Ferrari
, Joyce Oommen
, Sebastien Malinge
, Richard B. Lock
, Ursula R. Kees
, Rishi S. Kotecha

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e300-e303
Number of pages	4
Journal	Haematologica
Volume	104
Issue number	7
DOIs	https://doi.org/10.3324/haematol.2018.192906
Publication status	Published - 30 Jun 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3324/haematol.2018.192906

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601077/

Combinatorial therapeutics in high-risk infant acute lymphoblastic leukaemia
Kotecha, R. (Investigator 01)
NHMRC National Health and Medical Research Council
1/01/18 → 31/12/21
Project: Research

Cite this

Cheung, L. C., Cruickshank, M. N., Hughes, A. M., Singh, S., Chua, G.-A., Ford, J., Ferrari, E., Oommen, J., Malinge, S., Lock, R. B., Kees, U. R., & Kotecha, R. S. (2019). Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia. Haematologica, 104(7), e300-e303. https://doi.org/10.3324/haematol.2018.192906

@article{d07400968a3a4bada7ebdfc3d93ba3a5,

title = "Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia",

author = "Cheung, \{Laurence C.\} and Cruickshank, \{Mark N.\} and Hughes, \{Anastasia M.\} and Sajla Singh and Grace-Alyssa Chua and Jette Ford and Emanuela Ferrari and Joyce Oommen and Sebastien Malinge and Lock, \{Richard B.\} and Kees, \{Ursula R.\} and Kotecha, \{Rishi S.\}",

year = "2019",

month = jun,

day = "30",

doi = "10.3324/haematol.2018.192906",

language = "English",

volume = "104",

pages = "e300--e303",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "7",

}

Cheung, LC, Cruickshank, MN, Hughes, AM, Singh, S, Chua, G-A, Ford, J, Ferrari, E, Oommen, J, Malinge, S, Lock, RB, Kees, UR & Kotecha, RS 2019, 'Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia', Haematologica, vol. 104, no. 7, pp. e300-e303. https://doi.org/10.3324/haematol.2018.192906

Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia. / Cheung, Laurence C.; Cruickshank, Mark N.; Hughes, Anastasia M. et al.
In: Haematologica, Vol. 104, No. 7, 30.06.2019, p. e300-e303.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia

AU - Cheung, Laurence C.

AU - Cruickshank, Mark N.

AU - Hughes, Anastasia M.

AU - Singh, Sajla

AU - Chua, Grace-Alyssa

AU - Ford, Jette

AU - Ferrari, Emanuela

AU - Oommen, Joyce

AU - Malinge, Sebastien

AU - Lock, Richard B.

AU - Kees, Ursula R.

AU - Kotecha, Rishi S.

PY - 2019/6/30

Y1 - 2019/6/30

U2 - 10.3324/haematol.2018.192906

DO - 10.3324/haematol.2018.192906

M3 - Letter

C2 - 30679330

SN - 0390-6078

VL - 104

SP - e300-e303

JO - Haematologica

JF - Haematologica

IS - 7

ER -

Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia

UN SDGs

Access to Document

Projects

Combinatorial therapeutics in high-risk infant acute lymphoblastic leukaemia

Cite this